First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.
Ying Jie Chee, Sanchalika Acharyya, Huiling Liew et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the vascular and molecular effects of dapagliflozin, metformin, and their combination in 60 newly diagnosed type 2 diabetes mellitus patients over 12 weeks. The study found that dapagliflozin significantly reduced carotid intima-media thickness compared to metformin (-0.058 mm; p=0.018), although no significant differences were observed in reactive hyperaemia index among the groups.
Key findings
- Dapagliflozin reduced carotid intima-media thickness by -0.058 mm compared to metformin (p=0.018).
- No significant differences in reactive hyperaemia index were found between treatment groups.
- Sphingolipid profiling showed dapagliflozin-specific downregulation of pro-inflammatory lactosylceramide species.
- Proteomics indicated upregulation of EpCAM and downregulation of endothelial adhesion molecules with dapagliflozin.
Why it matters
Understanding the vascular effects of different first-line therapies for type 2 diabetes is crucial for optimizing patient outcomes. The findings suggest that dapagliflozin may offer additional cardiovascular benefits compared to metformin, which could influence treatment decisions.